Lori Melançon

Vice President, Corporate Affairs

Lori Melançon joined Rubius in 2018, and serves as Vice President of Corporate Affairs, leading internal and external communications, patient advocacy and corporate social responsibility. Prior to her role at Rubius, she was the Head of Corporate Affairs at Onyx Pharmaceuticals (acquired by Amgen), where she served on the leadership team and oversaw internal and external communications, global patient advocacy and provided investor relations support to Amgen for Onyx Pharmaceuticals.

Earlier in her career, she held corporate, product and marketing communications positions at WeissComm Partners, now W2O Group, a healthcare communications agency, Applied Biosystems, now Thermo Fischer Scientific, and ReGen Biologics, now Stryker. She began her career working on political campaigns in her home state of California.

Lori holds an MBA from the University of San Francisco and a B.A. in Rhetoric and Communications from the University of California, Davis.